Stock Performance and Market Context
On the day it hit Rs.950, Venus Remedies opened with a gap up of 4.07%, touching an intraday high at this record level. Despite a slight dip of 0.09% by the close, the stock’s performance remained in line with the sector, which saw a marginal decline of 0.16%. The stock has demonstrated notable momentum, gaining for two consecutive days and delivering a 2.39% return during this period.
Venus Remedies is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling strong technical support. The stock’s intraday volatility was elevated at 294.91%, reflecting active trading interest and price fluctuations on the day of the milestone.
Long-Term Outperformance Against Benchmarks
The company’s stock has outpaced the broader market significantly over various time horizons. Over the past year, Venus Remedies delivered a remarkable 220.92% return compared to the Sensex’s modest 1.63%. Year-to-date, the stock has gained 18.91%, while the Sensex declined by 11.55%. Over three years, the stock’s return of 473.26% dwarfs the Sensex’s 29.99%, and over a decade, Venus Remedies has surged 853.03%, far exceeding the Sensex’s 205.47% growth.
Shorter-term performance also highlights the stock’s strength, with 1-month and 3-month returns of 21.23% and 18.63% respectively, contrasting with the Sensex’s negative returns of -9.67% and -10.85% over the same periods.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Financial Strength and Profitability Metrics
Venus Remedies’ financials underpin its stock performance. The company reported a 96.37% growth in operating profit in the December 2025 quarter, marking a very positive earnings trend. Profit after tax (PAT) for the quarter stood at Rs.25.58 crores, reflecting a robust growth rate of 116.9%. This marks the fifth consecutive quarter of positive results, signalling consistent operational strength.
The company’s return on capital employed (ROCE) reached a high of 13.99% in the half-year period, while the inventory turnover ratio also peaked at 6.58 times, indicating efficient asset utilisation. Return on equity (ROE) is at a fair 10.5%, supported by a low average debt-to-equity ratio of zero, highlighting a clean balance sheet with minimal leverage.
Valuation metrics show the stock trading at a premium relative to peers, with a price-to-book value of 2.1. The company’s PEG ratio stands at 0.1, reflecting strong profit growth relative to its price appreciation over the past year.
Institutional Participation and Market Capitalisation
Institutional investors have increased their stake by 0.67% in the previous quarter, now collectively holding 3.28% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and growth prospects. Venus Remedies is classified as a micro-cap stock, which often presents unique growth opportunities within the Pharmaceuticals & Biotechnology sector.
Sector and Industry Positioning
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies has demonstrated resilience and growth in a competitive industry. The stock’s performance has consistently outpaced sector averages, with its recent all-time high underscoring its leadership among peers.
Curious about Venus Remedies Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Growth Considerations and Risks
While Venus Remedies has demonstrated impressive profit growth and stock performance, its net sales have grown at a moderate annual rate of 6.29% over the past five years. This slower top-line growth contrasts with the rapid expansion in profitability, suggesting a focus on margin improvement and operational efficiency.
The company’s strong financial discipline, reflected in its zero debt and improving profitability metrics, has contributed to its market outperformance. However, the relatively modest sales growth rate is a factor to monitor in assessing the sustainability of its current valuation premium.
Summary of Ratings and Market Position
Venus Remedies currently holds a Mojo Score of 74.0 and a Mojo Grade of Buy, upgraded from Hold on 12 Mar 2026. This upgrade reflects improved fundamentals and positive earnings momentum. The company’s micro-cap status and sector positioning make it a notable performer within Pharmaceuticals & Biotechnology.
Despite a slight negative day change of 0.09% on the day of the all-time high, the stock’s overall trajectory remains strongly positive, supported by consistent quarterly earnings growth, efficient capital utilisation, and increasing institutional participation.
Conclusion
Venus Remedies Ltd’s achievement of a new all-time high at Rs.950 marks a significant milestone in its growth journey. The stock’s sustained gains, robust profitability, and strong financial metrics underpin this achievement. While sales growth remains moderate, the company’s focus on operational excellence and margin expansion has driven substantial shareholder returns over multiple time frames. This milestone reflects Venus Remedies’ established position as a high-performing micro-cap within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
